February 25, 2019 / 6:17 AM / 7 months ago

Novartis licenses rights to RNA-targeting cardio drug from Ionis

ZURICH, Feb 25 (Reuters) - Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.

"We're excited about the novel, RNA-targeting approach that could be a gamechanger for people with elevated Lp(a)," said John Tsai, Novartis's drug development head. "If our Phase 3 trial succeeds, we expect that TQJ230 will become the leading treatment option."

Reporting by John Miller; editing by Thomas Seythal

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below